Liu Chun-Yi, Chen William Tzu-Liang, Kung Pei-Tseng, Chiu Chang-Fang, Wang Yueh-Hsin, Shieh Shwn-Huey, Tsai Wen-Chen
Department of Health Services Administration, China Medical University, 91 Hsueh-Shih Road, Taichung 40402, Taiwan.
BMC Cancer. 2014 Jun 17;14:446. doi: 10.1186/1471-2407-14-446.
Colorectal cancer is the third most commonly diagnosed cancer worldwide. Few studies have addressed the causes and risks of treatment refusal in a universal health insurance setting.
We examined the characteristics and survival associated with treatment refusal in patients with newly diagnosed colorectal cancer in Taiwan during 2004-2008. Treatment refusal was defined as not undergoing any cancer treatment within 4 months of confirmed cancer diagnosis. Patient data were extracted from four national databases. Factors associated with treatment refusal were identified through logistic regression using the generalized estimating equation method, and survival analysis was performed using the Cox proportional hazards model.
Of the 41,340 new colorectal cancer cases diagnosed, 3,612 patients (8.74%) refused treatment. Treatment refusal rate was higher in patients with less urbanized areas of residence, lower incomes, preexisting catastrophic illnesses, cancer stages of 0 and IV, and diagnoses at regional and district hospitals. Logistic regression analysis revealed that patients aged >75 years were the most likely to refuse treatment (OR, 1.87); patients with catastrophic illnesses (OR, 1.66) and stage IV cancer (OR, 1.43) had significantly higher refusal rates. The treatment refusers had 2.66 times the risk of death of those who received treatment. Factors associated with an increased risk of death in refusers included age ≥ 75 years, insured monthly salary ≥ 22,801 NTD, low-income household or aboriginal status, and advanced cancer stage (especially stage IV; HR, 11.33).
Our results show a lower 5-year survival for colorectal patients who refused treatment than for those who underwent treatment within 4 months. An age of 75 years or older, low-income household status, advanced stages of cancer, especially stage IV, were associated with higher risks of death for those who refused treatment.
结直肠癌是全球第三大常见诊断癌症。在全民健康保险环境下,很少有研究探讨治疗拒绝的原因和风险。
我们研究了2004年至2008年台湾新诊断结直肠癌患者中与治疗拒绝相关的特征和生存情况。治疗拒绝定义为在确诊癌症后4个月内未接受任何癌症治疗。患者数据从四个国家数据库中提取。使用广义估计方程法通过逻辑回归确定与治疗拒绝相关的因素,并使用Cox比例风险模型进行生存分析。
在41340例新诊断的结直肠癌病例中,3612例患者(8.74%)拒绝治疗。居住在城市化程度较低地区、收入较低、患有重大疾病、癌症分期为0期和IV期以及在地区和区级医院确诊的患者治疗拒绝率较高。逻辑回归分析显示,年龄>75岁的患者最有可能拒绝治疗(比值比,1.87);患有重大疾病(比值比,1.66)和IV期癌症(比值比,1.43)的患者拒绝率显著更高。拒绝治疗者的死亡风险是接受治疗者的2.66倍。拒绝治疗者死亡风险增加的相关因素包括年龄≥75岁、月投保薪资≥22801新台币、低收入家庭或原住民身份以及癌症晚期(尤其是IV期;风险比,11.33)。
我们的结果显示,拒绝治疗的结直肠癌患者的5年生存率低于在4个月内接受治疗的患者。75岁及以上、低收入家庭状况、癌症晚期,尤其是IV期,与拒绝治疗者的较高死亡风险相关。